首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1245675

全球腫瘤浸潤淋巴細胞免疫治療市場：市場機會、臨床試驗趨勢 (2028)

Global Tumor Infiltrating Lymphocytes Therapy Market Opportunity & Clinical Trials Insight 2028

出版日期: 2023年03月01日 | 出版商:

KuicK Research | 英文 300 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

本報告研究了全球腫瘤浸潤淋巴細胞免疫療法市場，並提供了市場概覽以及藥物趨勢、臨床試驗趨勢、區域趨勢和市場進入者的競爭格局。

內容

第 1 章腫瘤浸潤淋巴細胞 (TIL)：簡介

第2章腫瘤浸潤淋巴細胞免疫療法的出現

腫瘤浸潤淋巴細胞作為預後生物標誌物
腫瘤浸潤淋巴細胞免疫療法的聯合方法

第 3 章癌症的腫瘤浸潤淋巴細胞免疫治療方法：正在進行的臨床試驗和趨勢

黑色素瘤
結腸癌
消化道癌症
胃癌
胰腺癌
肝細胞癌（肝癌）
肺癌
非小細胞肺癌
婦科癌症
卵巢癌
子宮/子宮內膜癌
宮頸癌
泌尿生殖系統癌症
膀胱/尿路上皮癌
腎細胞癌 (RCC)
前列腺癌
頭頸癌
乳腺癌
血癌
腦腫瘤

第4章全球腫瘤浸潤淋巴細胞免疫治療臨床管線概況

按公司
按國家
根據指示
按患者分類
按階段

第 5 章全球腫瘤浸潤淋巴細胞免疫療法臨床管道，按公司、按適應症、按階段

臨床前
臨床
第一階段
第一階段/第二階段
第二階段
預註冊

第 6 章：公司對腫瘤浸潤淋巴細胞免疫療法專有技術的見解

第七章腫瘤浸潤淋巴細胞免疫治療市場趨勢及發展

第八章全球腫瘤浸潤淋巴細胞免疫治療市場分析

第9章腫瘤浸潤淋巴細胞免疫治療市場動態

市場驅動力
市場挑戰

第 10 章腫瘤浸潤淋巴細胞免疫療法的未來市場展望

第11章競爭格局

Adaptimmune
AgonOx
Cellular Biomedicine Group
Cellular Therapeutics
GRIT Biotechnology
Hebei Senlang Biotechnology
ImmuneCyte
Instil Bio
Intima Bioscience
Iovance Biotherapeutics
Lyell Immunopharma
National Cancer Institute (USA)
National Institutes of Health (USA)
Nurix
Obsidian Therapeutics
OriginCell Therapeutics
RootPath
Shanghai Gencells Therapeutics
SQZ Biotech
Turnstone Biologics

簡介目錄圖表

“Global Tumor Infiltrating Lymphocytes Therapy Market Opportunity & Clinical Trials Insight 2028” Report Highlights:

First TIL Therapy Commercial Availability By 2024
TIL Therapy Future Market Opportunity Assessment: > USD 400 million
Global TIL Therapies Clinical Pipeline By Company, Indication & Phase
Insight On More Than 30 TIL Therapies In Pipeline
TIL Therapy Proprietary Technologies Insight By Companies
TIL Therapy By Cancer: Ongoing Clinical Trials & Trends

The field of cell therapy has witnessed rapid evolution over the past few years, with various innovative technologies being developed to target and treat different types of cancer. One such therapy is tumor infiltrating lymphocyte (TIL) therapy which involves extraction of TILs from a patient's tumor, expanding them in a lab and then infusing them back into the patient to target cancer cells. Emergence of such therapy opens an unexplored window of personalized therapy. With gathered curiosity from the pharmaceutical industry TIL therapy has created itself a secured market space in the cancer treatment landscape.

The TIL therapy market is expected to see significant growth in the coming years due to its potential to provide durable, long term responses in patients with advanced or metastatic cancers. Personalized medicine is one of the major drivers of the TIL therapy market as it enables the therapy to be tailored to the specific needs to each patient. Companies such as Iovance Biotherapeutics and TILT Biotherapeutics are at the forefront of developing personalized TIL therapies, with Iovance's lead candidate Lifileucel already collecting significant attention from regulatory bodies around the world.

Another factor driving the growth of TIL therapy market is the increasing prevalence of cancer worldwide. With cancer rates on the rise, there is a growing need for effective therapies that can provide long term remission or cure. TIL therapy has shown promise in providing durable responses in patients with advanced cancers, including melanoma and cervical cancer. Moreover, government regulations also play a crucial role in shaping the competitive landscape of TIL therapy market.

The FDA has granted Fast Track and Breakthrough Therapy designations to some TIL therapies in pipeline, expediting the regulatory process and allowing them to reach the market faster. This has led to an increase in investment in TIL therapy research and development by pharmaceutical and biotech companies, further fueling the market's growth. For instance, Lifileucel has bagged FDA RMAT (Regenerative Medicine Advanced therapy) designation, FDA BTA (Breakthrough Therapy Designation) for different cancer indications, increasing its anticipated arrival in the market.

The emergence of combination therapies is another trend that is expected to shape the competitive landscape of TIL therapy in the coming years. To create a wider market reach and more penetration, companies which adopt combination strategies gain an advantage of fashioning an already secured target patient population. Iovance Biotherapeutics has adopted a similar approach by testing various combinations of Lifileucel with other immunotherapies in different cancer indications. This does not only expand Lifileucel's expected onset but the collaborative agreements done in order to start such combinational trials bring more investment to the company and ultimately increase their market share.

In terms of competition, the TIL therapy market is relatively nascent with only a handful of players currently in the space. However with the potential for significant growth in the market more companies are expected to enter the fray in the coming years. Currently, major players in the TIL therapy market include; Iovance Biotherapeutics, TILT Biotherapeutics, Instill Bio, Achilles Therapeutics and others. These companies are various stages of clinical development have demonstrated that their respective candidates have the potential to potentially lead the TIL therapy market.

For now, the arrival of first ever TIL therapy product is expected to enter the market by the end of 2023 or most by the beginning of 2024. Lifileucel is the most anticipated product in this emerging market as its clinical results in monotherapy or in combination with other immunotherapies have been the most widely acceptable. Furthermore, it can also be expected that after the approval of Lifileucel, as more companies enter the market, 1 more drug can bag its FDA approval in 5-6 years.

As this emerging market continues to grow, it is likely that more companies will enter the space leading to increased competition and innovation. TIL therapy market is poised for significant growth in the coming years, driven by various factors but mainly by the demand of novel therapies. As the technology evolves and manufacturing process becomes more scalable, TIL therapy has the potential to become a major player in the cancer treatment market landscape with expected market opportunity reach beyond US$400 Million by 2028.

1. Tumor Infiltrating Lymphocytes (TIL): A Brief Introduction

1.1 Overview
1.2 TIL History & Concept

2. Emergence Of Tumor Infiltrating Lymphocytes Therapy

2.1 Tumor Infiltrating Lymphocytes As Prognostic Biomarkers
2.2 Tumor Infiltrating Lymphocytes Therapy Combinational Approach

3. Tumor Infiltrating Lymphocytes Therapy Approaches By Cancer: Ongoing Clinical Trials & Trends

3.1 Melanoma
3.2 Colorectal Cancer
3.3 Gastrointestinal Cancers
3.4 Gastric Cancer
3.5 Pancreatic Cancer
3.6 Hepatocellular Carcinoma (Liver Cancer)
3.7 Lung Cancers
3.8 Non Small Cell Lung Cancer
3.9 Gynecological Carcinomas
3.10 Ovarian Cancer
3.11 Uterine/Endometrial Cancer
3.12 Cervical Cancer
3.13 Genitourinary Cancers
3.14 Bladder/Urothelial Carcinoma
3.15 Renal Cell Carcinoma (RCC)
3.16 Prostate Cancer
3.17 Head & Neck Cancer
3.18 Breast Cancer
3.19 Blood Cancer
3.20 Brain Tumors

4. Global Tumour Infiltrating Lymphocyte Therapies Clinical Pipeline Overview

4.1 Company
4.2 Country
4.3 By Indication
4.4 Patient Segment
4.5 By Phase

5. Global Tumour Infiltrating Lymphocyte Therapies Clinical Pipeline By Company, Indication & Phase

5.1 Preclinical
5.2 Clinical
5.3 Phase-I
5.4 Phase-I/II
5.5 Phase-II
5.6 Preregistration

6. Tumor Infiltrating Lymphocytes Therapy Proprietary Technologies Insight By Companies

7. Tumor Infiltrating Lymphocytes Therapy Market Trends & Development

7.1 Market Collaborations
7.2 Clinical Outlook

8. Global Tumor Infiltrating Lymphocytes Therapy Market Analysis

8.1 Growing Frontier for Tumor Infiltrating Lymphocyte Therapy Market as Personalized Treatment
8.2 Current Market Scenario
8.3 Therapy Cost Analysis

9. Tumor Infiltrating Lymphocytes Therapy Market Dynamics

9.1 Market Drivers
9.2 Market Challenges

10. Tumor Infiltrating Lymphocytes Therapy Future Market Outlook

11. Competitive Landscape

11.1 Adaptimmune
11.2 AgonOx
11.3 Cellular Biomedicine Group
11.4 Cellular Therapeutics
11.5 GRIT Biotechnology
11.6 Hebei Senlang Biotechnology
11.7 ImmuneCyte
11.8 Instil Bio
11.9 Intima Bioscience
11.10 Iovance Biotherapeutics
11.11 Lyell Immunopharma
11.12 National Cancer Institute (USA)
11.13 National Institutes of Health (USA)
11.14 Nurix
11.15 Obsidian Therapeutics
11.16 OriginCell Therapeutics
11.17 RootPath
11.18 Shanghai Gencells Therapeutics
11.19 SQZ Biotech
11.20 Turnstone Biologics

簡介目錄圖表

List of Figures

Figure 1-1: Procedure of Tumor Infiltrating Lymphocytes Therapy
Figure 1-2: Evolution of Tumor Infiltrating Lymphocytes (TIL) Therapy
Figure 2-1: Combinational Approaches In TILs For Different Cancer Indications
Figure 3-1: Benefits of Tumor Infiltrating Lymphocytes (TIL) in Cancer
Figure 3-2: Evaluation Of Tumor Infiltrating Lymphocytes in Solid Tumors
Figure 3-3: Therapies Used in Combination with Tumor Infiltrating Lymphocytes Therapy
Figure 3-4: Tumor Infiltrating Lymphocytes as Adjuvant Therapy of Melanoma
Figure 3-5: Iovance Biotherapeutics - Melanoma - C-144-01 Trial - Study Initiation & Expected Completion Year
Figure 3-6: Karolinska University Hospital - Melanoma - MAT02 Trial - Study Initiation & Expected Completion Year
Figure 3-7: Role of Tumor Infiltrating Lymphocytes in Colorectal Cancer
Figure 3-8: Colorectal Cancer - M.D. Anderson Cancer Center - MDA-TIL Trial - Study Initiation & Expected Completion Year
Figure 3-9: Colorectal Cancer - NCI - TIL Trial - Study Initiation & Expected Completion Year
Figure 3-10: Colorectal Cancer - University of Pittsburgh - TIL Trial - Study Initiation & Expected Completion Year
Figure 3-11: Global - Number of Newly Diagnosed Cases of Leading Gastrointestinal Cancer, 2020
Figure 3-12: Global - Number of Deaths by Leading Gastrointestinal Cancer, 2020
Figure 3-13: Tumor Infiltrating lymphocytes In Management Of Gastrointestinal Cancer
Figure 3-14: TILs Responsible For Microsatellite Instability In Gastric Cancer
Figure 3-15: Gastric Cancer - University of Pittsburgh -TIL Trial - Study Initiation & Expected Completion Year
Figure 3-16: Gastric Cancer - Fujian Medical University - Study Initiation & Expected Completion Year
Figure 3-17: Gastric Cancer - Intima Biosciences - Study Initiation & Expected Completion Year
Figure 3-18: Pancreatic Cancer - Juncell Therapeutics - Study Initiation & Expected Completion Year
Figure 3-19: Pancreatic Cancer - Shanghai Biomed-Union Biotechnology - Study Initiation & Expected Completion Year
Figure 3-20: Infiltrated T-Cells Assisting the Prognosis of Liver Cancer
Figure 3-21: Hepatocellular Carcinoma - Guangdong Zhaotai InVivo Biomedicine - Study Initiation & Expected Completion Year
Figure 3-22: Hepatocellular Carcinoma - Shanghai Juncell Therapeutics - Study Initiation & Expected Completion Year
Figure 3-23: TIL Therapy for Lung Cancer
Figure 3-24: Type of Infiltrated T-Cells in Lung Cancer
Figure 3-25: Lung Cancer - Guangdong Zhaotai InVivo Biomedicine - Study Initiation & Expected Completion Year
Figure 3-26: Role Of Tumor Infiltrating Lymphocytes In Non-Small Cell Lung Cancer
Figure 3-27: Non-Small Cell Lung Cancer - Iovance Biotherapeutics - Lifileucel/LN-145 TIL Therapy - Study Initiation & Expected Completion Year
Figure 3-28: Non-Small Cell Lung Cancer -Iovance Biotherapeutics - LN-145 TIL Therapy - Study Initiation & Expected Completion Year
Figure 3-29: Non-Small Cell Lung Cancer -Iovance Biotherapeutics - IOV-4001 TIL Therapy - Study Initiation & Expected Completion Year
Figure 3-30: Non-Small Cell Lung Cancer - Cellular Biomedicine - C-TIL051 TIL Therapy - Study Initiation & Expected Completion Year
Figure 3-31: Non-Small Cell Lung Cancer - Moffitt Cancer and Research Institute - Study Initiation & Expected Completion Year
Figure 3-32: Non-Small Cell Lung Cancer - Origin Cell Therapeutics - Study Initiation & Expected Completion Year
Figure 3-33: Non-Small Cell Lung Cancer - Intima Biosciences - CISH Inactivated TILs - Study Initiation & Expected Completion Year
Figure 3-34: Non-Small Cell Lung Cancer - BlueHorse Therapeutics - LM103 Injection - Study Initiation & Expected Completion Year
Figure 3-35: Non-Small Cell Lung Cancer - Lyell Immunopharma - LYL-845 TIL Therapy - Study Initiation & Expected Completion Year
Figure 3-36: Non-Small Cell Lung Cancer - Instil Bio - ITIL-306 TIL Therapy - Study Initiation & Expected Completion Year
Figure 3-37: Non-Small Cell Lung Cancer - Micorbio Co Ltd - MS-20 TIL Therapy - Study Initiation & Expected Completion Year
Figure 3-38: Non-Small Cell Lung Cancer - NCI -TIL Therapy - Study Initiation & Expected Completion Year
Figure 3-39: Global - Number of Newly Diagnosed Cases of Leading Gynecological Cancer, 2020
Figure 3-40: Global - Number of Deaths by Leading Gynecological Cancer, 2020
Figure 3-41: Role of Tumor Infiltrating Lymphocytes in Various Gynecological Cancer
Figure 3-42: Gynecological Cancer - Junshi Therapeutics -TIL Therapy - Study Initiation & Expected Completion Year
Figure 3-43: Gynecological Cancer - Junshi Therapeutics - GC203 TIL Therapy - Study Initiation & Expected Completion Year
Figure 3-44: Gynecological Cancer - Junshi Therapeutics - GC201 TIL Therapy - Study Initiation & Expected Completion Year
Figure 3-45: TILs Therapy for Ovarian Cancer
Figure 3-46: Tumor Infiltrating Lymphocytes In Prognosis Of Ovarian Cancer
Figure 3-47: Ovarian Cancer - NCI - TIL Trial - Study Initiation & Expected Completion Year
Figure 3-48: Ovarian Cancer - Herlev Hospital - Relatilimab-Nivolumab & TIL Trial - Study Initiation & Expected Completion Year
Figure 3-49: Ovarian Cancer - Iovance Biotherapeutics - LN-145 & Ln-145-S1 TIL Trial - Study Initiation & Expected Completion Year
Figure 3-50: Ovarian Cancer Targeting Tumor Infiltrating Lymphocytes Therapies in Clinical Trials
Figure 3-51: Tumor Infiltrating Lymphocytes In Prognosis Of Endometrial Cancer
Figure 3-52: Endometrial Cancer - Nurix Therapeutics - DeTIL-0255 TIL Therapy - Study Initiation & Expected Completion Year
Figure 3-53: TILs With Prognostic Significance In Cervical Cancer
Figure 3-54: Cervical Cancer - Fudan University - C-TIL052A Injection - Study Initiation & Expected Completion Year
Figure 3-55: Cervical Cancer - OriginCell Therapeutics - TIL Therapy - Study Initiation & Expected Completion Year
Figure 3-56: Cervical Cancer - Senlang Biotechnology - SL22P TIL Therapy - Study Initiation & Expected Completion Year
Figure 3-57: Cervical Cancer - Iovance Biotherapeutics - LN145 TIL Therapy - Study Initiation & Expected Completion Year
Figure 3-58: Global - Number of Newly Diagnosed Cases of Leading Genitourinary Cancer, 2020
Figure 3-59: Global - Number of Deaths by Leading Genitourinary Cancer, 2020
Figure 3-60: Infiltrated T-cells in Urothelial Cancer
Figure 3-61: Bladder Cancer - Sheba Medical Center - TIL Therapy - Study Initiation & Expected Completion Year
Figure 3-62: Infiltrated T-Cells in Renal Cell Carcinoma
Figure 3-63: Renal Cell Carcinoma - Instill Bio - ITIL-306 TIL Therapy - Study Initiation & Expected Completion Year
Figure 3-64: TIL Therapy For Prostate Cancer
Figure 3-65: TILs In Prognosis Of Prostate Cancer
Figure 3-66: Global - Newly Diagnosed Cases & Deaths related to Head & Neck Cancer, 2020
Figure 3-67: TIL Therapy Procedure For Targeting Head & Neck Cancer
Figure 3-68: TILs In Prognosis Of Head & Neck Cancer
Figure 3-69: Head & neck Cancer - LN-145 TIL Therapy - Study Initiation & Estimated Completion Year
Figure 3-70: Head & neck Cancer - TIL Therapy - Study Initiation & Estimated Completion Year
Figure 3-71: Global - Newly Diagnosed Cases & Deaths related to Breast Cancer (Million), 2020
Figure 3-72: Infiltrating T Cells Assisting In Prognosis Of Breast Cancer
Figure 3-73: TIL Therapy Procedure for Breast Cancer
Figure 3-74: Evaluation of TILs for Breast Cancer
Figure 3-75: Breast Cancer - Iovance Biotherapeutics - TIL Therapy - Study Initiation & Expected Completion Year
Figure 3-76: Breast Cancer - SOLTI Breast Cancer Research Group - NUMARZU-001 TIL Therapy - Study Initiation & Expected Completion Year
Figure 3-77: Breast Cancer - Juncell Therapeutics- GC 101 TILTherapy - Study Initiation & Expected Completion Year
Figure 3-78: Breast Cancer - The Affiliated Hospital of Qingdao University - HS-IT 101 TIL Therapy - Study Initiation & Expected Completion Year
Figure 3-79: Breast Cancer - Turnstone Biologics - TBio-4101 TIL Therapy - Study Initiation & Expected Completion Year
Figure 3-80: Global - Newly Diagnosed Cases by Leading Types of Blood Cancer, 2020
Figure 3-81: Global - Newly Diagnosed Cases by Leading Types of Blood Cancer, 2020
Figure 3-82: Infiltration of TILs In Leukemia
Figure 3-83: Tumor Infiltrating Lymphocytes Therapy Procedure in Leukemia
Figure 3-84: Type of Beneficial Infiltrating Cells in Leukemia
Figure 3-85: Global - Newly Diagnosed Cases & Deaths related to Brain Cancer, 2020
Figure 3-86: Role of Tumor Infiltrating Lymphocytes Therapy in Brain Tumor
Figure 3-87: Infiltrated T-Cells in Brain Tumor
Figure 3-88: Brain Cancer - Senlang Biotechnology - TIL Therapy - Study Initiation & Expected Completion Year
Figure 3-89: Brain Cancer - Juncell Therapeutics - TIL Therapy - Study Initiation & Expected Completion Year
Figure 4-1: Global - Tumour Infiltrating Lymphocyte Clinical Trials By Company, 2023 till 2028
Figure 4-2: Global - Tumour Infiltrating Lymphocyte Clinical Trials By Country, 2023 till 2028
Figure 4-3: Global - Tumour Infiltrating Lymphocyte Clinical Trials By Indicating, 2023 till 2028
Figure 4-4: Global - Tumour Infiltrating Lymphocyte Clinical Trials By Patient Segment, 2023 till 2028
Figure 4-5: Global - Tumour Infiltrating Lymphocyte Clinical Trials By Phase, 2023 till 2028
Figure 6-1: Instil Bio - Tumor Processing Method Releases & Preserves All Of The TILs From Tumor Samples
Figure 6-2: Instil Bio - ITIL-168 - Manufacturing & Treatment Process
Figure 6-3: Iovance Biotherapeutics - Steps For Gen 2 TIL Proprietary Technology
Figure 6-4: Iovance Biotherapeutics - Streamlined 22-day GMP Manufacturing Process
Figure 6-5: Design Of Nurix DEL Collection
Figure 6-6: Key Features Of DELigase Platform
Figure 6-7: Nurix's DNA Encoded Library In Drug Development
Figure 6-8: INTASYL Mechanism Of Action
Figure 6-9: PELEUS Three-Step Process
Figure 6-10: Current VELOS Manufacturing Process
Figure 6-11: TILT-123 Viral Construct
Figure 6-12: TILI-123 Mode Of Action
Figure 6-13: Selected TIL Approach
Figure 6-14: Virus Plus TIL Therapy
Figure 6-15: Structure Of A TALEN
Figure 6-16: TALEN Gene Editing
Figure 6-17: Various Gene Editing Mechanisms Enabled By TALEN
Figure 6-18: TALEN Technology Permits High Specific Cleavage
Figure 6-19: CYTODRIVE Platform
Figure 6-20: Novoleucel Steps Involved
Figure 6-21: TiL Manufacturing Process
Figure 8-1: US - Minimum & Maximum Cost of Tumor Infiltrating Lymphocytes Therapy Treatment, October'2020
Figure 8-2: Proleukin - Cost of Single Powder for Injection, Single Day & Full Treatment (US$), October'2020
Figure 8-3: Cyclophosphamide - Cost of various Supplies of Powder for Injection (US$), October'2020
Figure 8-4: Cyclophosphamide - Price of 2.5ml Supply & Price per ml of Intravenous Solution (US$), October'2020
Figure 8-5: Cyclophosphamide - Average Cost of Single Day & Full Treatment (US$), October'2020
Figure 8-6: Fludarabine - Average Cost of Single Day & Full Treatment (US$), October'2020
Figure 9-1: Driving Forces for Tumor Infiltrating Therapy Market
Figure 9-2: Factors Challenging The Market Growth Of TIL Therapy
Figure 10-1: Global - Global Tumor Infiltrating Lymphocytes Therapy Market Forecast (US$ Million), 2023 - 2028
Figure 10-2: Global - Future Drivers for Tumor Infiltrating Lymphocyte Therapy Market
Figure 10-3: Global - Future Regional Powers for Tumor Infiltrating Lymphocyte Therapy Market